Table 1. Baseline characteristics of study population.
| Placebo (n = 20) | Elamipretide (n = 19) | |
|---|---|---|
| Demographic | ||
| Age (years, mean [±SD]) | 69 (4) | 68 (3.4) |
| Sex, Female (number [%]) | 7 (35.0) | 11 (57.9) |
| White (number [%]) | 20 (100.0) | 18 (94.7) |
| Clinical | ||
| BMI (kg/m2, mean [±SD]) | 26.1 (2.8) | 26.5 (4.3) |
| SBP (mm Hg, mean [±SD]) | 124.3 (13) | 121.1 (12.9) |
| Laboratory | ||
| Sodium (mEq/dL, mean [±SD]) | 137.7 (1.5) | 137.5 (1.6) |
| Hemoglobin (gm/dL, mean [±SD]) | 13.5 (0.9) | 13.1 (0.9) |
| eGFR MDRD, (mL/[min · 1.73m2], mean [±SD]) | 81.5 (14.7) | 82 (10.6) |
| Medications | ||
| Statins (number [%]) | 5 (25.0) | 2 (10.5) |
BMI = body mass index; SBP = systolic blood pressure; eGFR MDRD = estimated glomerular filtration rate.